Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Liquid biopsy for the management of NSCLC patients under osimertinib treatment.

Critical reviews in clinical laboratory sciences - 1 Aug 2024

Ntzifa Aliki, Marras Theodoros, Georgoulias Vasilis, Lianidou Evi

Abstract excerpt

Therapeutic management of NSCLC patients is quite challenging as they are mainly diagnosed at a late stage of disease, and they present a high heterogeneous molecular profile. Osimertinib changed the paradigm shift in treatment of EGFR mutant NSCLC patients achieving significantly better clinical outcomes. To date, osimertinib is successfully administered not only as first- or second-line treatment, but also as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Indoles

Share to Liquid Biopsy

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 38305080
DOI: 10.1080/10408363.2024.2302116

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Liquid biopsy for the management of NSCLC patients under osimertinib treatment.PMID 38305080Read ↗

Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatmentSemantic proximity Read ↗

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Semantic proximity Read ↗

Liquid Biopsy Testing for the Management of Patient with Non-Small Cell Lung Cancer Carrying a Rare Exon-20 EGFR Insertion.Semantic proximity Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.Semantic proximity Read ↗

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancerSemantic proximity Read ↗

The evolving role of liquid biopsy in lung cancer.Semantic proximity Read ↗

The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation.Semantic proximity Read ↗

Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.Semantic proximity Read ↗

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion.Semantic proximity Read ↗

Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.Semantic proximity Read ↗

Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.